Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy

BACKGROUND: Tocilizumab, a humanized monoclonal antibody, targets IL-6 receptors blocking downstream pro-inflammatory effects of IL-6. In preliminary reports it was suggested to be beneficial in patients with severe COVID-19. METHODS: In this open-label prospective study we describe clinical charact...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Eur J Intern Med
Egile Nagusiak: Morena, Valentina, Milazzo, Laura, Oreni, Letizia, Bestetti, Giovanna, Fossali, Tommaso, Bassoli, Cinzia, Torre, Alessandro, Cossu, Maria Vittoria, Minari, Caterina, Ballone, Elisabetta, Perotti, Andrea, Mileto, Davide, Niero, Fosca, Merli, Stefania, Foschi, Antonella, Vimercati, Stefania, Rizzardini, Giuliano, Sollima, Salvatore, Bradanini, Lucia, Galimberti, Laura, Colombo, Riccardo, Micheli, Valeria, Negri, Cristina, Ridolfo, Anna Lisa, Meroni, Luca, Galli, Massimo, Antinori, Spinello, Corbellino, Mario
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: European Federation of Internal Medicine. Published by Elsevier B.V. 2020
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7241995/
https://ncbi.nlm.nih.gov/pubmed/32448770
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejim.2020.05.011
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak